DEC003M in Prostate Cancer

This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.

Trial Details

NCT ID
NCT07657806
Phase
PHASE1
Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • DEC003M
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • At the time of informed consent, be ≥18 years of age.
  • Histologically confirmed adenocarcinoma of the prostate.
  • Metastatic castration-resistant prostate cancer (mCRPC) with documented disease progression despite androgen deprivation therapy.
  • Prior orchiectomy or medical castration, or continuous treatment with luteinizing hormone releasing hormone analogues (LHRHa) .

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →